Aware Super Pty Ltd as trustee of Aware Super acquired a new position in DaVita Inc. (NYSE:DVA - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,115 shares of the company's stock, valued at approximately $316,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Invesco Ltd. increased its holdings in shares of DaVita by 20.9% in the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after purchasing an additional 275,284 shares in the last quarter. Amundi grew its position in DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company's stock worth $68,726,000 after buying an additional 240,126 shares during the period. Skandinaviska Enskilda Banken AB publ increased its holdings in DaVita by 256.8% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company's stock valued at $24,301,000 after buying an additional 116,758 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock valued at $99,846,000 after acquiring an additional 92,014 shares during the period. Finally, California Public Employees Retirement System grew its holdings in shares of DaVita by 75.1% in the 4th quarter. California Public Employees Retirement System now owns 196,788 shares of the company's stock worth $29,430,000 after acquiring an additional 84,375 shares during the period. Institutional investors and hedge funds own 90.12% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the company. Barclays lifted their price objective on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research report on Friday, February 21st. Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, StockNews.com raised shares of DaVita from a "hold" rating to a "buy" rating in a report on Thursday, April 10th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, DaVita presently has a consensus rating of "Hold" and an average target price of $166.33.
Get Our Latest Stock Report on DaVita
DaVita Price Performance
DVA stock traded down $5.80 during trading on Monday, hitting $134.24. The stock had a trading volume of 180,357 shares, compared to its average volume of 832,174. The stock has a market cap of $10.74 billion, a price-to-earnings ratio of 12.50, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The company's 50 day moving average price is $149.13 and its two-hundred day moving average price is $155.97. DaVita Inc. has a 1-year low of $128.69 and a 1-year high of $179.60.
DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, sell-side analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.
DaVita Company Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
